Bessemer Group
ESPR

Bessemer Group’s Esperion Therapeutics ESPR Stock Holding History

Bessemer Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-127
Closed – – 2543
2025
Q2 		$0 Hold
127
– – ﹤0.01% 2458
2025
Q1 		$0 Buy
+127
New +$234 ﹤0.01% 2518

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Bessemer Group's ESPR Position: Q3 2025 in Review

Bessemer Group sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 127 shares.

Bessemer Group first reported a position in ESPR in Q1 2025 and held it in 2 quarters. The position peaked at $0 in Q2 2025. 189 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Bessemer Group reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 127 Esperion Therapeutics shares in Q3 2025.
  • Bessemer Group first reported a position in Esperion Therapeutics in Q1 2025 and held it in 2 quarters.
  • Bessemer Group's Esperion Therapeutics position peaked at $0 in Q2 2025.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.